Published in PLoS One on December 12, 2013
Pharmacologic Approaches Against Advanced Glycation End Products (AGEs) in Diabetic Cardiovascular Disease. Res Cardiovasc Med (2015) 0.85
Association of Advanced Glycation End Products with coronary Artery Calcification in Japanese Subjects with Type 2 Diabetes as Assessed by Skin Autofluorescence. J Atheroscler Thromb (2016) 0.85
Skin autofluorescence predicts cardio-renal outcome in type 1 diabetes: a longitudinal study. Cardiovasc Diabetol (2016) 0.79
A new gender-specific model for skin autofluorescence risk stratification. Sci Rep (2015) 0.77
Genetic analysis of advanced glycation end products in the DHS MIND study. Gene (2016) 0.76
Skin advanced glycation end-products evaluation in infants according to the type of feeding and mother's smoking habits. SAGE Open Med (2016) 0.75
Antioxidant, antiglycation and insulinotrophic properties of Coccinia grandis (L.) in vitro: Possible role in prevention of diabetic complications. J Tradit Complement Med (2016) 0.75
Smoking, Vascular Events, and ESRD in Patients With CKD. Am J Kidney Dis (2016) 0.75
Skin Autofluorescence and Mortality in Patients on Peritoneal Dialysis. Medicine (Baltimore) (2015) 0.75
Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis (2009) 18.60
The pathobiology of diabetic complications: a unifying mechanism. Diabetes (2005) 14.96
Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature (2000) 12.33
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int (2004) 4.51
Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology (2005) 2.74
Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia (2004) 2.56
Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens (2003) 2.45
The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int (2003) 2.43
Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol (2000) 1.92
Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol (2005) 1.82
The receptor of advanced glycation end products plays a central role in advanced oxidation protein products-induced podocyte apoptosis. Kidney Int (2012) 1.77
Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care (2007) 1.73
Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care (2007) 1.59
The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J (2003) 1.33
Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int (1997) 1.18
Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: an overview of current clinical studies, evidence, and limitations. Diabetes Technol Ther (2006) 1.18
Simple noninvasive measurement of skin autofluorescence. Ann N Y Acad Sci (2005) 1.17
Autofluorescence of human skin is age-related after correction for skin pigmentation and redness. J Invest Dermatol (2001) 1.15
Advanced glycation end products and mortality in hemodialysis patients. Kidney Int (2002) 1.12
Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease. Metabolism (2008) 1.10
Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3. Clin J Am Soc Nephrol (2011) 1.09
Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol (1996) 1.02
Advanced glycation end-products: implications for diabetic and non-diabetic nephropathies. Diabetes Metab (2009) 0.99
Skin autofluorescence is associated with renal function and cardiovascular diseases in pre-dialysis chronic kidney disease patients. Nephrol Dial Transplant (2010) 0.97
Reference values for the Chinese population of skin autofluorescence as a marker of advanced glycation end products accumulated in tissue. Diabet Med (2011) 0.94
TRC4186, a novel AGE-breaker, improves diabetic cardiomyopathy and nephropathy in Ob-ZSF1 model of type 2 diabetes. J Cardiovasc Pharmacol (2009) 0.94
Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes. Kidney Int Suppl (2007) 0.94
Skin autofluorescence is associated with severity of vascular complications in Japanese patients with Type 2 diabetes. Diabet Med (2012) 0.93
Measurement of advanced glycation endproducts in skin of patients with rheumatoid arthritis, osteoarthritis, and dialysis-related spondyloarthropathy using non-invasive methods. Rheumatol Int (2007) 0.93
AGEs, autofluorescence and renal function. Nephrol Dial Transplant (2008) 0.91
Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: is there oxidative stress in uremia? Kidney Int (1998) 0.90
Advanced glycation end products, carotid atherosclerosis, and circulating endothelial progenitor cells in patients with end-stage renal disease. Metabolism (2010) 0.88
Relationship of skin autofluorescence to cardiovascular disease in Japanese hemodialysis patients. Ther Apher Dial (2010) 0.87
Advanced glycation end products in patients with cerebral infarction. Intern Med (2009) 0.87
Carbonyl stress: increased carbonyl modification of proteins by autoxidation products of carbohydrates and lipids in uremia. Int J Artif Organs (1999) 0.77
A novel plasminogen activator inhibitor-1 inhibitor, TM5441, protects against high-fat diet-induced obesity and adipocyte injury in mice. Br J Pharmacol (2016) 0.75
Plasminogen activator inhibitor-1 regulates macrophage-dependent postoperative adhesion by enhancing EGF-HER1 signaling in mice. FASEB J (2017) 0.75
A Case of Lipoprotein Glomerulopathy with apoE Chicago and apoE (Glu3Lys) Treated with Fenofibrate. Case Rep Nephrol Dial (2017) 0.75